Hyundai Bioscience Co., Ltd. (048410)

Overview

Hyundai Bioscience Co., Ltd. is a pioneering biotechnology company based in Seoul, South Korea. Founded in the year 2000, the company has been at the forefront of developing innovative solutions in the biotechnological sector. Hyundai Bioscience is dedicated to the research, development, and commercialization of novel products and treatments aimed at improving human health. With a focus on addressing some of the most pressing medical challenges, the company leverages cutting-edge science to create impactful solutions.

Products and Services

• Vitabrid C12

This flagship vitamin C product by Hyundai Bioscience represents a significant advancement in skincare technology. Vitabrid C12 is specifically formulated to deliver active vitamin C deep into the skin. By utilizing a unique, patented technology, this product ensures that the skin receives a continuous supply of vitamin C for over 12 hours. This innovative approach to skincare helps in promoting collagen production, reducing the appearance of fine lines and wrinkles, and protecting the skin from harmful environmental factors.

• Polytaxel

Hyundai Bioscience has also made significant strides in the field of oncology with the development of Polytaxel. This novel drug formulation is designed to treat pancreatic cancer and solid tumors. Polytaxel is a testament to the company’s commitment to pioneering new cancer treatments, offering hope to patients struggling with these devastating diseases. Its development underscores Hyundai Bioscience's dedication to improving the outcomes and quality of life for cancer patients through innovative therapeutic options.

• CP-COV03

In response to the global COVID-19 pandemic, Hyundai Bioscience has developed CP-COV03, a drug aimed at combating the virus. This therapeutic solution represents a significant milestone in the company's endeavor to address urgent public health crises. CP-COV03 is part of Hyundai Bioscience's broader efforts to contribute to the global fight against COVID-19, showcasing the company's agility in responding to emerging health threats and its commitment to public well-being.